Generic Drug Approvals Still Winning The Pandemic At US FDA
Productivity remains high as full ANDA approvals reached a FY 2020 peak and complete responses dropped to another low in June.
You may also be interested in...
Biosimilar development programs also are expected to increase, a promising sign for the growing sector, but those fees remained unchanged.
New drug review elements that could benefit complex generics include a two-month filing review period before the user fee clock is triggered, more interaction between the agency and a sponsor during the review, and an opportunity for a company to have in-depth discussions with the FDA after receipt of a complete response letter, Teva’s Scott Tomsky says at kick-off meeting for next iteration of the generic drug user fee agreement.
New drug approvals dropped, likely because of a new focus on COVID-19 treatments, while generic drug approvals increased.